$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx

$egrx Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000082787121000016 Filed on May 10, 2021

Income Statement

Concept	2021 Q1	2020 Q1
Revenue	$41.25M	$46.02M
YoY Change	-10.37%	-7.56%
Cost Of Revenue	$8.442M	$4.765M
YoY Change	77.17%	-50.13%
Gross Profit	$32.81M	$41.26M
YoY Change	-20.48%	12.46%
Gross Profit Margin	79.53%	89.65%
Selling, General & Admin	$19.88M	$24.76M
YoY Change	-19.7%	36.46%
% of Gross Profit	60.59%	60.0%
Research & Development	$14.29M	$9.427M
YoY Change	51.56%	47.87%
% of Gross Profit	43.55%	22.85%
Depreciation & Amortization	$200.0K	$251.0K
YoY Change	-20.32%	3.72%
% of Gross Profit	0.61%	0.61%
Operating Expenses	$34.17M	$34.18M
YoY Change	-0.04%	-9.13%
Operating Profit	-$3.773M	$4.035M
YoY Change	-193.51%	-66.84%
Interest Expense	$422.0K	$889.0K
YoY Change	-52.53%	29.59%
% of Operating Profit		22.03%
Other Income/Expense, Net	$5.113M	-$7.043M
YoY Change	-172.6%	3568.23%
Pretax Income	$1.340M	-$3.008M
YoY Change	-144.55%	-125.11%
Income Tax	$1.761M	-$137.0K
% Of Pretax Income	131.42%
Net Earnings	-$421.0K	-$2.871M
YoY Change	-85.34%	-132.0%
Net Earnings / Revenue	-1.02%	-6.24%
Basic Earnings Per Share	-$0.03	-$0.21
Diluted Earnings Per Share	-$0.03	-$0.21
COMMON SHARES
Basic Shares Outstanding	13.07M shares	13.67M shares
Diluted Shares Outstanding	13.07M shares	13.67M shares

Balance Sheet

Concept	2021 Q1	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$105.2M	$202.0M
YoY Change	-47.92%	97.85%
Cash & Equivalents	$105.2M	$202.0M
Short-Term Investments
Other Short-Term Assets	$5.157M	$691.0K
YoY Change	646.31%	72.32%
Inventory	$6.862M	$8.434M
Prepaid Expenses
Receivables	$44.87M	$54.49M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$164.0M	$275.6M
YoY Change	-40.49%	51.22%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.270M	$2.423M
YoY Change	-6.31%	3.86%
Goodwill	$39.74M	$39.74M
YoY Change	0.0%	0.0%
Intangibles	$12.21M	$14.92M
YoY Change	-18.14%	-14.63%
Long-Term Investments
YoY Change
Other Assets	$27.48M	$15.53M
YoY Change	76.95%	335.62%
Total Long-Term Assets	$95.98M	$86.37M
YoY Change	11.13%	11.85%
TOTAL ASSETS
Total Short-Term Assets	$164.0M	$275.6M
Total Long-Term Assets	$95.98M	$86.37M
Total Assets	$260.0M	$361.9M
YoY Change	-28.17%	39.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$12.56M	$9.756M
YoY Change	28.73%	-41.88%
Accrued Expenses	$21.41M	$20.12M
YoY Change	6.42%	-10.31%
Deferred Revenue	$4.317M	$6.019M
YoY Change	-28.28%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$8.000M	$116.0M
YoY Change	-93.1%	2220.0%
Total Short-Term Liabilities	$41.97M	$145.9M
YoY Change	-71.23%	229.88%
LONG-TERM LIABILITIES
Long-Term Debt	$23.25M	$30.78M
YoY Change	-24.46%	-16.81%
Other Long-Term Liabilities	$3.664M	$3.454M
YoY Change	6.08%	20.35%
Total Long-Term Liabilities	$26.92M	$34.24M
YoY Change	-21.38%	-14.13%
TOTAL LIABILITIES
Total Short-Term Liabilities	$41.97M	$145.9M
Total Long-Term Liabilities	$26.92M	$34.24M
Total Liabilities	$68.89M	$180.1M
YoY Change	-61.75%	114.19%
SHAREHOLDERS EQUITY
Retained Earnings	$84.07M	$69.63M
YoY Change	20.74%	3.68%
Common Stock	$17.00K	$17.00K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$205.3M	$172.9M
YoY Change	18.78%	12.32%
Treasury Stock Shares	3.713M shares	2.933M shares
Shareholders Equity	$191.1M	$181.8M
YoY Change
Total Liabilities & Shareholders Equity	$260.0M	$361.9M
YoY Change	-28.17%	39.5%

Cashflow Statement

Concept	2021 Q1	2020 Q1
OPERATING ACTIVITIES
Net Income	-$421.0K	-$2.871M
YoY Change	-85.34%	-132.0%
Depreciation, Depletion And Amortization	$200.0K	$251.0K
YoY Change	-20.32%	3.72%
Cash From Operating Activities	$10.48M	$3.158M
YoY Change	231.79%	-87.94%
INVESTING ACTIVITIES
Capital Expenditures	$384.0K	$472.0K
YoY Change	-18.64%	166.67%
Acquisitions
YoY Change
Other Investing Activities	-$5.000M	-$17.50M
YoY Change	-71.43%
Cash From Investing Activities	-$5.384M	-$17.97M
YoY Change	-70.04%	10053.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$1.432M	$999.0K
YoY Change	43.34%
Debt Paid & Issued, Net	$2.000M	$1.000M
YoY Change	100.0%	-60.0%
Cash From Financing Activities	-$3.020M	$107.1M
YoY Change	-102.82%	-4130.69%
NET CHANGE
Cash From Operating Activities	$10.48M	$3.158M
Cash From Investing Activities	-$5.384M	-$17.97M
Cash From Financing Activities	-$3.020M	$107.1M
Net Change In Cash	$2.074M	$92.24M
YoY Change	-97.75%	295.07%
FREE CASH FLOW
Cash From Operating Activities	$10.48M	$3.158M
Capital Expenditures	$384.0K	$472.0K
Free Cash Flow	$10.09M	$2.686M
YoY Change	275.8%	-89.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000827871
CY2021Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q1	dei	Amendment Flag AmendmentFlag	false
CY2021Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:AccruedLiabilitiesCurrent
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesNoncurrent
CY2021Q1	dei	Document Type DocumentType	10-Q
CY2021Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2021Q1	dei	Document Period End Date DocumentPeriodEndDate	2021-03-31
CY2021Q1	dei	Entity Registrant Name EntityRegistrantName	Eagle Pharmaceuticals, Inc.
CY2021Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q1	dei	Entity File Number EntityFileNumber	001-36306
CY2021Q1	dei	Local Phone Number LocalPhoneNumber	326-5300
CY2021Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-8179278
CY2021Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	50 Tice Boulevard
CY2021Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 315
CY2021Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Woodcliff Lake
CY2021Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2021Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07677
CY2021Q1	dei	City Area Code CityAreaCode	(201)
CY2021Q1	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value per share
CY2021Q1	dei	Trading Symbol TradingSymbol	EGRX
CY2021Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2021Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2021Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021Q1	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	13109367	shares
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	105229000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	103155000	USD
CY2021Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	44868000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	50678000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	6862000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	8075000	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7027000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4157000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	163986000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	166065000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2270000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2077000	USD
CY2021Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	12211000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	12917000	USD
CY2021Q1	us-gaap	Goodwill Goodwill	39743000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	39743000	USD
CY2021Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	14278000	USD
CY2020Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	15180000	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	27480000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	17208000	USD
CY2021Q1	us-gaap	Assets Assets	259968000	USD
CY2020Q4	us-gaap	Assets Assets	253190000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	12559000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6268000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	21414000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	23817000	USD
CY2021Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	8000000	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	8000000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	41973000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	38085000	USD
CY2021Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3664000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3959000	USD
CY2021Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	23253000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	25135000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	68890000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	67179000	USD
CY2021Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2021Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16858031	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16739203	shares
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	17000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	17000	USD
CY2021Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	312323000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	305403000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	84068000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	84489000	USD
CY2021Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	3712571	shares
CY2020Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	3682176	shares
CY2021Q1	us-gaap	Treasury Stock Value TreasuryStockValue	205330000	USD
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	203898000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	191078000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	186011000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	259968000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	253190000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	41249000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	46020000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8442000	USD
CY2020Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4765000	USD
CY2021Q1	us-gaap	Royalty Expense RoyaltyExpense	2413000	USD
CY2020Q1	us-gaap	Royalty Expense RoyaltyExpense	3038000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14288000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9427000	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	19879000	USD
CY2020Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	24755000	USD
CY2021Q1	us-gaap	Costs And Expenses CostsAndExpenses	45022000	USD
CY2020Q1	us-gaap	Costs And Expenses CostsAndExpenses	41985000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3773000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	4035000	USD
CY2021Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	35000	USD
CY2020Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	346000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	422000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	889000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5500000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-6500000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5113000	USD
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7043000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1340000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3008000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1761000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-137000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-421000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-2871000	USD
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13069373	shares
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13667606	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13069373	shares
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13667606	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	186011000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6508000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1963000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-1551000	USD
CY2021Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	1432000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-421000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	191078000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	179174000	USD
CY2020Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1276000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7472000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	330000	USD
CY2020Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	999000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-2871000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	181830000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-421000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-2871000	USD
CY2021Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	902000	USD
CY2020Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-90000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	190000	USD
CY2020Q1	us-gaap	Depreciation Depreciation	251000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	252000	USD
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	221000	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	706000	USD
CY2020Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	666000	USD
CY2021Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	5600000	USD
CY2020Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-6500000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	6508000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7472000	USD
CY2021Q1	us-gaap	Debt Securities Held To Maturity Credit Loss Expense Reversal DebtSecuritiesHeldToMaturityCreditLossExpenseReversal	100000	USD
CY2020Q1	us-gaap	Debt Securities Held To Maturity Credit Loss Expense Reversal DebtSecuritiesHeldToMaturityCreditLossExpenseReversal	0	USD
CY2021Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	118000	USD
CY2020Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	65000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-5810000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6487000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1213000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1868000	USD
CY2021Q1	egrx	Increase Decreasein Prepaid Expenseand Other Current Assets Total IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal	2870000	USD
CY2020Q1	egrx	Increase Decreasein Prepaid Expenseand Other Current Assets Total IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal	-4473000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	6291000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4294000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2403000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-8238000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Assets And Liabilities Net IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet	318000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Noncurrent Assets And Liabilities Net IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet	1230000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	10478000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3158000	USD
CY2021Q1	egrx	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	0	USD
CY2020Q1	egrx	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	17500000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	384000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	472000	USD
CY2021Q1	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	5000000	USD
CY2020Q1	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	0	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5384000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-17972000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1963000	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	330000	USD
CY2021Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1551000	USD
CY2020Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1276000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	110000000	USD
CY2021Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2000000	USD
CY2020Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1000000	USD
CY2021Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1432000	USD
CY2020Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	999000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3020000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	107055000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2074000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	92241000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	103155000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	109775000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	105229000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	202016000	USD
CY2021Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	267000	USD
CY2020Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	24000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	321000	USD
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	576000	USD
CY2021Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2020Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	842000	USD
CY2021Q1	us-gaap	Basis Of Accounting BasisOfAccounting	Interim Condensed Consolidated Financial StatementsThe accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for reporting quarterly information. Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. The condensed consolidated balance sheet at December 31, 2020 was derived from audited financial statements, but certain information and footnote disclosures normally included in our annual consolidated financial statements have been condensed or omitted. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary for the fair presentation of the financial information for the interim periods reported have been made. Results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results for the year ending December 31, 2021 or any period thereafter. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC on March 5, 2021.
CY2021Q1	egrx	Number Of Products Launched NumberOfProductsLaunched	3	product
CY2021Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These financial statements are presented in U.S. dollars and are prepared in accordance with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements including disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period and </span></div>accompanying notes. Our critical accounting policies are those that are both most important to our financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. We anticipate that the COVID-19 pandemic will continue to disrupt our supply chain and marketing and sales efforts for certain of our products, including Bendeka, although it is not currently expected that any disruption would be significant. As of the date of issuance of these financial statements, we are not aware of any specific event or circumstance that would require us to update our estimates, assumptions and judgments or revise the carrying value of our assets or liabilities. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates, and any such differences may be material to our financial statements.
CY2021Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform with the current year presentation, including for amounts related to accounts receivable, net and prepaid expenses and other current assets. None of the amounts pertaining to the reclassifications were significant.</span></div>
CY2021Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	101799000	USD
CY2021Q1	us-gaap	Receivables Fair Value Disclosure ReceivablesFairValueDisclosure	4624000	USD
CY2021Q1	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Asset EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset	276000	USD
CY2021Q1	us-gaap	Other Assets Fair Value Disclosure OtherAssetsFairValueDisclosure	17800000	USD
CY2021Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	124499000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	79682000	USD
CY2020Q4	us-gaap	Other Assets Fair Value Disclosure OtherAssetsFairValueDisclosure	12200000	USD
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	91882000	USD
CY2020Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021Q1	us-gaap	Revenue Performance Obligation Description Of Payment Terms RevenuePerformanceObligationDescriptionOfPaymentTerms	Receivables from our product sales have payment terms ranging from 30 to 75 days with select extended terms to wholesalers on initial purchases of product launch quantities. Our receivables from royalty revenue are due 45 days from the end of the quarter.
CY2021Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	314000	USD
CY2020Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	1113000	USD
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2960369	shares
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3181083	shares
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-421000	USD
CY2020Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2871000	USD
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13069373	shares
CY2021Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7652000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7268000	USD
CY2021Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5382000	USD
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13667606	shares
CY2021Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2020Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2021Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	13069373	shares
CY2020Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	13667606	shares
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5191000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2270000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2077000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	190000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	251000	USD
CY2021Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	3089000	USD
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	3515000	USD
CY2021Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	0	USD
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	2589000	USD
CY2021Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	3773000	USD
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1971000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	6862000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	8075000	USD
CY2021Q1	egrx	Prepaid Fda User Fee PrepaidFDAUserFee	1210000	USD
CY2020Q4	egrx	Prepaid Fda User Fee PrepaidFDAUserFee	1262000	USD
CY2021Q1	us-gaap	Prepaid Insurance PrepaidInsurance	225000	USD
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	191000	USD
CY2021Q1	egrx	Advances To Commercial Manufacturers AdvancesToCommercialManufacturers	435000	USD
CY2020Q4	egrx	Advances To Commercial Manufacturers AdvancesToCommercialManufacturers	660000	USD
CY2021Q1	us-gaap	Other Assets Current OtherAssetsCurrent	5157000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2044000	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7027000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4157000	USD
CY2021Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4317000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4966000	USD
CY2021Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	4936000	USD
CY2020Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	5996000	USD
CY2021Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	3046000	USD
CY2020Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	4686000	USD
CY2021Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1942000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2370000	USD
CY2021Q1	egrx	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	3904000	USD
CY2020Q4	egrx	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	2724000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1148000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1123000	USD
CY2021Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2121000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1952000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	21414000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	23817000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P3Y9M18D
CY2021Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	343000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	1323000	USD
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	343000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	1323000	USD
CY2021Q1	us-gaap	Lease Cost LeaseCost	343000	USD
CY2020	us-gaap	Lease Cost LeaseCost	1323000	USD
CY2021Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	855000	USD
CY2021Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y9M18D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y1M6D
CY2021Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.060
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.060
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1148000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3664000	USD
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	4812000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	23100000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	10889000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	12211000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	23100000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	10183000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	12917000	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	706000	USD
CY2020Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	666000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	1916000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1369000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1570000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1898000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1520000	USD
CY2021Q1	egrx	Finite Lived Intangible Assets Expected Amortization After Year Four FiniteLivedIntangibleAssetsExpectedAmortizationAfterYearFour	3938000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	12211000	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3096161	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	600200	shares
CY2020Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	15971	shares
CY2020Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	60294	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3620096	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3331890	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	71500	shares
CY2021Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	56107	shares
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	208374	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3138909	shares
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6508000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7472000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6508000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7472000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5377000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1048000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1423000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1455000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1038000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	413000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	0	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	0	USD
CY2021Q1	us-gaap	Long Term Debt LongTermDebt	32000000	USD
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	6000000	USD
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	26000000	USD
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0	USD
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	0	USD
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	0	USD
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	0	USD
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	0	USD
CY2021Q1	us-gaap	Purchase Obligation PurchaseObligation	66057000	USD
CY2021Q1	us-gaap	Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear	66057000	USD
CY2021Q1	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	0	USD
CY2021Q1	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	0	USD
CY2021Q1	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	0	USD
CY2021Q1	us-gaap	Purchase Obligation Due In Fourth Year PurchaseObligationDueInFourthYear	0	USD
CY2021Q1	us-gaap	Purchase Obligation Due In Fifth Year PurchaseObligationDueInFifthYear	0	USD
CY2021Q1	us-gaap	Contractual Obligation ContractualObligation	103434000	USD
CY2021Q1	us-gaap	Purchase Obligation Due After Fifth Year PurchaseObligationDueAfterFifthYear	0	USD
CY2021Q1	us-gaap	Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear	73105000	USD
CY2021Q1	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	27423000	USD
CY2021Q1	us-gaap	Contractual Obligation Due In Second Year ContractualObligationDueInSecondYear	1455000	USD
CY2021Q1	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	1038000	USD
CY2021Q1	us-gaap	Contractual Obligation Due In Fourth Year ContractualObligationDueInFourthYear	413000	USD
CY2021Q1	us-gaap	Contractual Obligation Due In Fifth Year ContractualObligationDueInFifthYear	0	USD
CY2021Q1	us-gaap	Contractual Obligation Due After Fifth Year ContractualObligationDueAfterFifthYear	0	USD
CY2021Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	325000	USD
CY2020Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	286000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5377000	USD
CY2021Q1	us-gaap	Purchase Obligation PurchaseObligation	66057000	USD
CY2021Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	8000000.0	USD
CY2021Q1	us-gaap	Deferred Finance Costs Noncurrent Gross DeferredFinanceCostsNoncurrentGross	700000	USD
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	6000000	USD
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	26000000	USD
CY2021Q1	us-gaap	Long Term Debt LongTermDebt	32000000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1761000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-137000	USD
CY2021Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	1.31
CY2020Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.05
CY2021Q1	egrx	Number Of Tax Jurisdictions Currently Auditing The Company NumberOfTaxJurisdictionsCurrentlyAuditingTheCompany	3	jurisdiction
CY2021Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2021Q1	us-gaap	Debt Securities Held To Maturity Credit Loss Expense Reversal DebtSecuritiesHeldToMaturityCreditLossExpenseReversal	100000	USD
CY2021Q1	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Asset EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset	300000	USD

Files In Submission

Name	View Source	Status
0000827871-21-000016-index-headers.html	Edgar Link	pending
0000827871-21-000016-index.html	Edgar Link	pending
0000827871-21-000016.txt	Edgar Link	pending
0000827871-21-000016-xbrl.zip	Edgar Link	pending
egrx-20210331.htm	Edgar Link	pending
egrx-20210331.xsd	Edgar Link	pending
egrx-20210331_cal.xml	Edgar Link	unprocessable
egrx-20210331_def.xml	Edgar Link	unprocessable
egrx-20210331_htm.xml	Edgar Link	completed
egrx-20210331_lab.xml	Edgar Link	unprocessable
egrx-20210331_pre.xml	Edgar Link	unprocessable
exhibit311q12021.htm	Edgar Link	pending
exhibit312q12021.htm	Edgar Link	pending
exhibit321q12021.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx

2021 Q1 Form 10-Q Financial Statement

#000082787121000016 Filed on May 10, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EGRX EAGLE PHARMACEUTICALS, INC. Stock $egrx

2021 Q1 Form 10-Q Financial Statement

#000082787121000016 Filed on May 10, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx